The state health plan currently has a $507 million deficit. Pharmacy benefit managers, the intermediaries in the drug supply chain, are supposed to use their bargaining power to negotiate lower drug ...

Teenage diabetes is rising alarmingly in the U.S., with poor diet and sugary food habits being primary culprits. Early detection and lifestyle changes can significantly reduce the risk of Type 2 ...

According to the Centers for Disease Control and Prevention (CDC), sugary drinks are the primary source of added sugars in the American diet, contributing to a host of health issues […] ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon confirm that.

BROWNSVILLE — It was an unusually cold Saturday morning in the Rio Grande Valley but that didn't stop hundreds of people from forming a line that wound throughout the south side of the Brownsville ...

By Dr. Sanchari Sinha Dutta, Ph.D. GLP1R gene variants link to cardiometabolic traits and behavioral changes, but findings suggest behavioral effects of GLP1RA are indirect Study: Association of GLP1R ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity ...

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...

New research suggests that factors like age, sex, body fat and the amount of sugar in your blood play a significant role in the progression from pre-diabetes to a type 2 diabetes diagnosis.

Overweight scores continue from 25-30. And over 30 is obese. Quetelet merely used this early calculation as a descriptor. He did not make any medical proclamations. The Quetelet Index became ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.